Company Monitoring Page for Amgen

job ratings (see below graph) for Amgen

latest headlines for company on cafepharma

Amgen talks long-term growth, but doubts remain for analysts, investors
Fierce Pharma
Tue, 02/8/22 - 11:54 pm
Tags:
Amgen, earnings
Amgen, Plexium Collaborate To Identify Novel Targeted Protein Degradation Therapies
NASDAQ
Thu, 02/3/22 - 11:34 am
Tags:
Amgen, Plexium, drug discovery, targeted protein degradation
Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig
Fierce Pharma
Tue, 02/1/22 - 11:28 pm
Tags:
Amgen, Novartis, Aimovig, migraines, SEC
Amgen Wins Another Key Approval for This Potential Blockbuster Cancer Drug
Motley Fool
Thu, 01/27/22 - 11:36 pm
Tags:
Amgen, Europe, Lumykras, non-small cell lung cancer
The top 10 biopharma M&A deals in 2021
Fierce Pharma
Tue, 01/18/22 - 10:53 am
Tags:
M&A, CSL, Vifor, Jazz Pharmaeuticals, GW Pharma, Novo Nordisk, Dicerna, Horizon Therapeutics, Viela Bio, Perrigo, HRA Pharma, Sanofi, Kadmon, Merck, Acceleron, Pfizer, Arena Pharmaceuticals, Translate Bio, Trillium Therapeutics, Amgen, Five Prime Therapeutics
JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says
Fierce Pharma
Thu, 01/13/22 - 11:06 am
Tags:
JPMHC 2022, Novartis, Leqvio, drug launches, Regeneron, Amgen, Sanofi
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
Tags:
FDA, adagrasib, donanemab, faricimab, lecanemab, tezepelumab, tirzepatide, vutrisiran, Eli Lilly, Mirati Therapeutics, Roche, Chugai, Eisai, Biogen, AstraZeneca, Amgen, Alnylam
JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch
Fierce Pharma
Wed, 01/12/22 - 11:22 pm
Tags:
JPMHC 2022, Bausch Health, Amgen, Eli Lilly, Perrigo, JNJ, Legend Biotech
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis; Sage touts double-duty anxiety drug
Fierce Biotech
Tue, 01/11/22 - 11:43 am
Tags:
JPMHC 2022, Freenome, Amgen, Roche, ThermoFisher Scientific
Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs
Fierce Biotech
Thu, 01/6/22 - 12:36 pm
Tags:
Amgen, Generate Biomedicines, biobucks, drug development, drug discovery, artificial intelligence
AstraZeneca, Amgen tap Brand Institute in new naming twist for their freshly approved Tezspire
Fierce Pharma
Thu, 01/6/22 - 11:52 am
Tags:
Amgen, AstraZeneca, Broad Institute, asthma, Tezspire, drug names
Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers
Fierce Pharma
Fri, 12/31/21 - 11:10 am
Tags:
patents, patent cliffs, Bristol Myers Squibb, Amgen, Pfizer, Revlimid, Eliquis, Enbrel, Otezla, Ibrance
Amgen builds Otezla’s psoriasis label as rival BMS looms large
Pharmaforum
Wed, 12/22/21 - 11:19 am
Tags:
Amgen, Otezla, psoriasis, Bristol Myers Squibb, deucravacitinib
Abandoned by Amgen, Cy­to­ki­net­ics lands $50M upfront deal for Chinese rights to heart failure prospect
Fierce Biotech
Tue, 12/21/21 - 10:34 am
Tags:
Cytokinetics, heart failure, Omecamtiv Mecarbil, Amgen, China, Ji Xing Pharmaceuticals
AstraZeneca and Amgen’s asthma biologic approved in the US
Biopharma Reporter
Mon, 12/20/21 - 11:08 am
Tags:
AstraZeneca, Amgen, Tezspire, FDA, severe asthma
Bowing to pressure, J.P. Morgan says its health care conference will be virtual
Stat
Wed, 12/15/21 - 10:53 am
Tags:
JPMHC 2022, virtual meetings, COVID-19, pandemic, Amgen, Moderna Therapeutics
Moderna, Amgen among biotech heavyweights pulling out of JPM conference over Covid concerns
Stat
Tue, 12/14/21 - 11:37 pm
Tags:
JPMHC 2022, Amgen, Moderna, Sarepta Therapeutics, COVID-19, pandemic, Omicron COVID-19 variant
Amgen halts some drug discounts for safety net hospitals as SCOTUS takes on 340B case
Endpoints
Thu, 12/2/21 - 11:04 pm
Tags:
Amgen, drug discounts, 340B
Amgen's Otezla notches win in genital psoriasis, snagging possible edge against forthcoming BMS rival
Fierce Pharma
Thu, 12/2/21 - 12:25 pm
Tags:
Amgen, Otezla, psoriasis, Bristol Myers Squibb
Amgen stalls Samsung's Enbrel biosim until 2029 in 2nd patent win of the year
Fierce Pharma
Wed, 12/1/21 - 10:14 am
Tags:
Amgen, Enbrel, Samsung, biosimilars, patents

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.